Session Description

During this case conference, Dr. David Flannery, Director of Telegenetics and Digital Genetics at Cleveland Clinic’s Center for Personalized Genetic Healthcare, will be presenting about a telemedicine genetic consult from his apartment to a mission clinic in Honduras. Dr. Flannery will demonstrate how he was able to connect with the telemedicine cart and peripheral devices from the internet, provided by satellite, to the clinic. After Dr. Flannery’s case presentation, Ms. Alisha Keehn and Ms. Megan Lyon, Associate Program Director and Project Manager for the NCC, respectively, will share resources, tools, and trainings that have been developed by the seven Regional Genetics Networks (RGNs), National Genetics Education and Family Support Center (Family Center), and NCC to support genetics providers who utilize telemedicine.

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Describe how telemedicine can be utilized in clinical genetic evaluation for individuals with dysmorphic features.
2. Identify telegenetic resources developed by the RGNs, Family Center, or NCC that can be utilized by genetics providers.
3. Identify the RGN in which you practice genetics.

 Faculty:

David Flannery, MD, FACMG

Director of Telegenetics and Digital Genetics, Cleveland Clinic Center for Personalized Genetic Healthcare

Alisha Keehn, MPA

Associate Project Director, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG

Megan Lyon, MPH

Project Manager, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG

Educational Credits are not offered

Target Audience

1. Clinical geneticists; genetic counselors; pediatric, obstetric, and maternal-fetal specialists; and all medical practitioners who are providing comprehensive diagnostic, management, and counseling services for patients with, or at risk for, genetically influenced health problems.
2. Laboratory directors and technicians who conduct genetic testing, researchers involved in the discovery of genetic disorders and treatments and any healthcare and public health professionals who have an in interest medical and clinical genetics and genomics.

Off-label Drug Use statement

When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.

Disclosures of Financial Relationships

Staff - American College of Medical Genetics and Genomics

The following have nothing to disclose.

Jane Radford, MHA, CHCP

Claudia Barnett

Maximilian Muenke, MD, FACMG

 Presenter Disclosures 

David Flannery, MD, FACMG

Director of Telegenetics and Digital Genetics, Cleveland Clinic Center for Personalized Genetic Healthcare

Has no relevant financial relationships to disclose.

Alisha Keehn, MPA

Associate Project Director, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG

Has no relevant financial relationships to disclose.

Megan Lyon, MPH

Project Manager, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG

Has no relevant financial relationships to disclose.